Name: Xenoview
Active Ingredient: hyperpolarized Xe-129
Indications: To evaluate pulmonary function and imaging
Approval Date: 12/23/2022
Company: Polarean, Inc.
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf
Name: Xenoview
Active Ingredient: hyperpolarized Xe-129
Indications: To evaluate pulmonary function and imaging
Approval Date: 12/23/2022
Company: Polarean, Inc.
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf